论文部分内容阅读
目的:探讨治疗前后不同时期非小细胞肺癌患者血清CEA、CYFRA21蛳1水平的变化规律及临床意义。方法:分别于化疗前、后采集非小细胞肺癌患者血清样本,采用放射免疫分析法检测患者血清CEA,CYFRA21蛳1含量,并对检测结果进行比较分析。结果:非小细胞肺癌患者CEA阳性率为59.2 %,其中鳞癌47.6 %,腺癌72.9 %。CYFRA21蛳1阳性率为65.1 %,其中鳞癌71.9 %,腺癌57.1 %。二者均随临床TNM分期增加而升高,手术后及化疗有效者CEA、CYFRA21蛳1逐渐降低。结论:动态检测患者CEA,CYFRA21蛳1水平对非小细胞肺癌的诊断、病程及转移情况、疗效及预后判断、监测复发有重要意义。
Objective: To investigate the changes and clinical significance of serum CEA and CYFRA21 蛳 1 levels in patients with non-small cell lung cancer before and after treatment. Methods: Serum samples of patients with non-small cell lung cancer were collected before and after chemotherapy. Serum CEA and CYFRA21 蛳 1 levels were measured by radioimmunoassay, and the results were compared. Results: The positive rate of CEA in non-small cell lung cancer was 59.2%, of which 47.6% were squamous cell carcinoma and 72.9% were adenocarcinoma. The positive rate of CYFRA21 蛳 1 was 65.1%, of which 71.9% were squamous cell carcinoma and 57.1% were adenocarcinoma. Both of them increased with the increase of clinical TNM staging. The CEA and CYFRA21 逐 1 after operation and chemotherapy were decreased gradually. Conclusion: The dynamic detection of CEA, CYFRA21 蛳 1 levels in non-small cell lung cancer diagnosis, course and metastasis, efficacy and prognosis, monitoring the recurrence of great significance.